Please login to the form below

Not currently logged in
Email:
Password:

cell and gene therapies

This page shows the latest cell and gene therapies news and features for those working in and with pharma, biotech and healthcare.

Hal Barron touts new drive to improve GSK’s research output

Hal Barron touts new drive to improve GSK’s research output

of therapies which will work in combination with these drugs. ... He also indicated GSK’s interest in cell and gene therapies – another reversal on previous strategy, where the company had sold off its Strimvelis gene therapy in early 2018.

Latest news

More from news
Approximately 3 fully matching, plus 44 partially matching documents found.

Latest Intelligence

  • Gene therapy market access Q&A Gene therapy market access Q&A

    Jesper Jorgensen, Health Economics and Market Access Manager, Cell and Gene Therapy Catapult gives his personal view on how to get the new therapies to patients. ... My job is to understand what it takes to get a product reimbursed, and how developers of

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    He’s seen a rapid change in attitudes towards healthcare systems in the last 12 months, as awareness of cell and gene therapy grows. ... Obenshain made it clear that the company is looking to lay the foundations for a long-term solution, which will

  • Cell and gene therapy Cell and gene therapy

    Minh Hong, head of commercial development for cell therapies at Swiss contract manufacturer Lonza, said: “There is so much variability between cell and gene therapies and each process at the moment, ... And even for allogeneic cell therapies and gene

  • Launch trends 2019 Launch trends 2019

    Companies also need to adapt to new commercialisation challenges for novel therapeutic modalities like gene and cell therapies. ... The transformational nature of some new therapies, eg cell and gene therapies, means the whole healthcare system delivery

  • Relearning launch: Four key dynamics for pharma launches in 2019 Relearning launch: Four key dynamics for pharma launches in 2019

    Gene and cell therapies, novel approaches to rare disease and drug replacements, like digital therapies, are about to crowd the market, creating gaps in education for physician and payer alike. ... an inflection point and quickly started a steep climb to

More from intelligence
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest appointments

  • Health comms agency emotive hires new cell and gene therapy leader Health comms agency emotive hires new cell and gene therapy leader

    An expert in cell and gene therapies, Dr Ferrari joins emotive following 20 years in research as well as holding medical affairs and commercial roles in biopharma and diagnostics. ... It is also charged with developing HCP engagement on gene silencing

  • Abeona Therapeutics appoints new additions to board of directors Abeona Therapeutics appoints new additions to board of directors

    Stefano Buono and Richard Van Duyne join the biopharma. Abeona Therapeutics, a clinical stage biopharmaceutical company focused on developing cell and gene therapies, has expanded its board of directors through the ... He said: “Abeona’s ambitious

  • Avita Medical appoints CEO Avita Medical appoints CEO

    chief scientific officer, global business development and licensing, and chief scientific officer for its cell and gene therapy unit. ... and gene therapies for Novartis subsidiaries Systemix Inc.

  • Paul Blake joins Oxford BioMedica Paul Blake joins Oxford BioMedica

    He will head the clinical development of the company's pipeline of gene and cell therapies. ... therapies will be important to Oxford BioMedica as we continue to develop our broad pipeline of novel gene and cell therapies.”.

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • Precision medicine with precision management and precision pricing; ensuring affordability in the cell and gene therapy era

    the cost curve to accommodate new and expensive cell and gene therapies.  In addition to this, insurance plans demand lower co-pays for hospital costs i.e. ... can. Potential methods of payment proposed for expensive cell and gene therapies include:.

  • Training the next generation of biotech leaders

    Novel technologies, coupled with programmes designed to drive cell and gene research and development, are ushering in a new era of therapies. ... The approval of two CAR-T therapies this year illustrates how cell and gene therapies are turning from

  • Life at the end of the Brexit tunnel

    An Advanced Therapies Treatment Centre to develop cell and gene therapies. ... Expansion of the Cell and Gene Therapy Manufacturing Centre in Stevenage.

  • Introduction to the manufacturing of biologics

    However, the broad definition of a biologic is they are created by either a microorganism or a mammalian cell, and are large, complex molecules; the majority of which are proteins or  ... polypeptides.  Examples of biologics  include blood or blood

  • The Clinical Trial Company

    The Clinical Trial Company (TCTC) targets medium size clinical trials and novel products which lack a classical road map to the market. ... TCTC are experts in advanced therapies, such as cell and gene therapies, as well as orphan drug and biologics.

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics